JP2010180210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010180210A5 JP2010180210A5 JP2010034701A JP2010034701A JP2010180210A5 JP 2010180210 A5 JP2010180210 A5 JP 2010180210A5 JP 2010034701 A JP2010034701 A JP 2010034701A JP 2010034701 A JP2010034701 A JP 2010034701A JP 2010180210 A5 JP2010180210 A5 JP 2010180210A5
- Authority
- JP
- Japan
- Prior art keywords
- antitumor
- drug
- agent
- inhibitor
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 53
- 229940041181 antineoplastic drug Drugs 0.000 claims 33
- 239000000203 mixture Substances 0.000 claims 9
- 239000000126 substance Substances 0.000 claims 7
- 229940034982 antineoplastic agent Drugs 0.000 claims 6
- 229960004562 carboplatin Drugs 0.000 claims 6
- 190000008236 carboplatin Chemical compound 0.000 claims 6
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 229960004316 cisplatin Drugs 0.000 claims 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- 239000002502 liposome Substances 0.000 claims 4
- 230000033616 DNA repair Effects 0.000 claims 3
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 3
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 230000022983 regulation of cell cycle Effects 0.000 claims 3
- 230000002195 synergetic effect Effects 0.000 claims 3
- 230000020172 G2/M transition checkpoint Effects 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 239000003277 telomerase inhibitor Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 230000008051 G1/S transition checkpoint Effects 0.000 claims 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 229940123582 Telomerase inhibitor Drugs 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 231100000337 synergistic cytotoxicity Toxicity 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32667101P | 2001-10-03 | 2001-10-03 | |
| US60/326,671 | 2001-10-03 | ||
| US34152901P | 2001-12-17 | 2001-12-17 | |
| US60/341,529 | 2001-12-17 | ||
| US35675902P | 2002-02-15 | 2002-02-15 | |
| US60/356,759 | 2002-02-15 | ||
| CA2,383,529 | 2002-04-23 | ||
| CA002383259A CA2383259A1 (en) | 2002-04-23 | 2002-04-23 | Synergistic compositions |
| US40198402P | 2002-08-07 | 2002-08-07 | |
| US60/401,984 | 2002-08-07 | ||
| US40873302P | 2002-09-06 | 2002-09-06 | |
| US60/408,733 | 2002-09-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532029A Division JP4778679B2 (ja) | 2001-10-03 | 2002-10-03 | 併用薬剤を送達するための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010180210A JP2010180210A (ja) | 2010-08-19 |
| JP2010180210A5 true JP2010180210A5 (enExample) | 2010-12-02 |
| JP4926256B2 JP4926256B2 (ja) | 2012-05-09 |
Family
ID=32475852
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532029A Expired - Lifetime JP4778679B2 (ja) | 2001-10-03 | 2002-10-03 | 併用薬剤を送達するための組成物 |
| JP2010034701A Expired - Lifetime JP4926256B2 (ja) | 2001-10-03 | 2010-02-19 | 併用薬剤を送達するための組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532029A Expired - Lifetime JP4778679B2 (ja) | 2001-10-03 | 2002-10-03 | 併用薬剤を送達するための組成物 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1432402B1 (enExample) |
| JP (2) | JP4778679B2 (enExample) |
| AT (1) | ATE345775T1 (enExample) |
| AU (1) | AU2002331480B2 (enExample) |
| CA (1) | CA2462369C (enExample) |
| CY (1) | CY1105953T1 (enExample) |
| DE (1) | DE60216305T2 (enExample) |
| DK (1) | DK1432402T3 (enExample) |
| ES (1) | ES2272768T3 (enExample) |
| IL (2) | IL161214A (enExample) |
| PT (1) | PT1432402E (enExample) |
| WO (1) | WO2003028696A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| WO2004087105A1 (en) * | 2003-04-02 | 2004-10-14 | Celator Pharmaceuticals, Inc. | Combination formulations of platinum agents and fluoropyrimidines |
| EP1608338A1 (en) * | 2003-04-02 | 2005-12-28 | Celator Technologies Inc. | Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| US20060240090A1 (en) * | 2003-04-02 | 2006-10-26 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| BRPI0511753A (pt) * | 2004-06-01 | 2008-01-02 | Terumo Corp | formulação de irinotecano e respectiva composição farmacêutica |
| AU2005269800B8 (en) | 2004-07-19 | 2011-12-01 | Celator Pharmaceuticals, Inc. | Particulate constructs for release of active agents |
| US20080213183A1 (en) * | 2004-09-20 | 2008-09-04 | Marcel Bally | Free or Liposomal Gemcitabine Alone or in Combination with Free or Liposomal Idarubicin |
| JP4638500B2 (ja) * | 2004-10-06 | 2011-02-23 | ビーシー キャンサー エージェンシー | 治療剤を封入するためのリポソームからなる組成物及び治療剤のリポソーム内での保持性を高めるための方法 |
| WO2007044748A2 (en) * | 2005-10-11 | 2007-04-19 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
| JP5687411B2 (ja) * | 2005-10-25 | 2015-03-18 | セレーター ファーマスーティカルズ、インク． | 固形腫瘍のための定率配合薬の治療 |
| WO2007076117A2 (en) * | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| EP2049106A2 (en) * | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20080248097A1 (en) * | 2007-02-26 | 2008-10-09 | Kwon Glen S | Polymeric micelles for combination drug delivery |
| WO2009022190A1 (en) * | 2007-08-16 | 2009-02-19 | Biocompatibles Uk Limited | Delivery of drug combinations |
| KR101563658B1 (ko) | 2007-11-28 | 2015-10-27 | 셀라토 파마슈티칼즈, 인코포레이티드 | 개선된 탁산 전달 시스템 |
| CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
| EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| CN107530283A (zh) * | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 组合脂质体药物制剂 |
| CN107614019A (zh) | 2015-03-09 | 2018-01-19 | 加利福尼亚大学董事会 | 用于组合抗癌疗法的聚合物‑药物结合物 |
| WO2017011685A1 (en) | 2015-07-15 | 2017-01-19 | Celator Pharmaceuticals, Inc. | Improved nanoparticle delivery systems |
| CN105434437B (zh) * | 2015-12-01 | 2018-03-02 | 山东大学 | 一种奥沙利铂和伊立替康类药物共载脂质体及其制备方法 |
| CN106619509B (zh) * | 2016-12-21 | 2020-02-18 | 山东大学 | 一种奥沙利铂和伊立替康共载载药脂肪乳及其制备方法 |
| WO2021183318A2 (en) * | 2020-03-09 | 2021-09-16 | President And Fellows Of Harvard College | Methods and compositions relating to improved combination therapies |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| WO2022140661A1 (en) * | 2020-12-23 | 2022-06-30 | Cascade Prodrug Inc. | Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL26210A (en) * | 1965-08-02 | 1970-12-24 | Merck & Co Inc | Pharmaceutical compositions containing substituted sulphoxides |
| JP3213471B2 (ja) * | 1994-04-13 | 2001-10-02 | ポーラ化成工業株式会社 | 薬効成分含有リポソーム製剤の製造方法 |
| CA2366908A1 (en) * | 1999-03-24 | 2000-09-28 | The Secretary Of State For Defence | Vaccine composition |
| JP2003524624A (ja) * | 1999-04-09 | 2003-08-19 | ジェシー エル エス オウ | 治療薬の組織への送達を高める方法及び組成物 |
| JP2003503313A (ja) * | 1999-06-03 | 2003-01-28 | ジェシー エル エス オウ | 細胞増殖及び細胞死を変調する方法及び組成物 |
| US6352996B1 (en) * | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| IL148372A0 (en) * | 1999-09-09 | 2002-09-12 | Univ California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
| CA2387145A1 (en) * | 1999-10-14 | 2001-04-19 | Valerio Ditizio | Liposome encapsulated silver salt compositions |
| US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| AU778659B2 (en) * | 2000-02-10 | 2004-12-16 | Liplasome Pharma A/S | Lipid-based drug delivery systems |
| AU2001249393A1 (en) * | 2000-03-22 | 2001-10-03 | Glaxo Group Limited | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
-
2002
- 2002-10-03 AU AU2002331480A patent/AU2002331480B2/en not_active Expired
- 2002-10-03 AT AT02766997T patent/ATE345775T1/de active
- 2002-10-03 JP JP2003532029A patent/JP4778679B2/ja not_active Expired - Lifetime
- 2002-10-03 DK DK02766997T patent/DK1432402T3/da active
- 2002-10-03 WO PCT/CA2002/001500 patent/WO2003028696A2/en not_active Ceased
- 2002-10-03 ES ES02766997T patent/ES2272768T3/es not_active Expired - Lifetime
- 2002-10-03 DE DE60216305T patent/DE60216305T2/de not_active Expired - Lifetime
- 2002-10-03 PT PT02766997T patent/PT1432402E/pt unknown
- 2002-10-03 EP EP02766997A patent/EP1432402B1/en not_active Expired - Lifetime
- 2002-10-03 CA CA002462369A patent/CA2462369C/en not_active Expired - Lifetime
- 2002-10-03 EP EP06009230A patent/EP1693052A1/en not_active Withdrawn
-
2004
- 2004-04-01 IL IL161214A patent/IL161214A/en active IP Right Grant
-
2007
- 2007-01-25 CY CY20071100100T patent/CY1105953T1/el unknown
-
2008
- 2008-01-15 IL IL188774A patent/IL188774A0/en unknown
-
2010
- 2010-02-19 JP JP2010034701A patent/JP4926256B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010180210A5 (enExample) | ||
| ES2964764T3 (es) | Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino | |
| Manegold et al. | Gemcitabine in non-small cell lung cancer (NSCLC) | |
| Hande | Topoisomerase II inhibitors | |
| JP2013503174A5 (enExample) | ||
| JP2013527232A5 (enExample) | ||
| KR20120004523A (ko) | Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제 | |
| Chen et al. | Engineered plant-derived nanovesicles facilitate tumor therapy: natural bioactivity plus drug controlled release platform | |
| CA2462369A1 (en) | Compositions for delivery of drug combinations | |
| RU2008141763A (ru) | Лечение рака молочной железы, негативного по трем рецепторам | |
| Nevins et al. | Nanotechnology approaches for prevention and treatment of chemotherapy‐induced neurotoxicity, neuropathy, and cardiomyopathy in breast and ovarian cancer survivors | |
| JP2005508920A5 (enExample) | ||
| NZ599878A (en) | Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents | |
| JP2011520921A5 (enExample) | ||
| JP2010523696A5 (enExample) | ||
| CN102772416A (zh) | 包含GSK-3β抑制剂和SBE7-β-CD的药物组合物 | |
| Tang et al. | Combination of baicalein and 10-hydroxy camptothecin exerts remarkable synergetic anti-cancer effects | |
| JP2007277240A5 (enExample) | ||
| Schultze et al. | Tretinoin-loaded lipid-core nanocapsules overcome the triple-negative breast cancer cell resistance to tretinoin and show synergistic effect on cytotoxicity induced by doxorubicin and 5-fluororacil | |
| Karati et al. | A comprehensive review on targeted cancer therapy: new face of treatment approach | |
| Kaneko et al. | Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells | |
| Iqubal et al. | A technical note on emerging combination approach involved in the onconanotherapeutics | |
| Patwekar et al. | Mechanistic insights on anticancer drugs with specific biological targets and signalling pathways | |
| JP2012508239A5 (enExample) | ||
| JP2012508240A5 (enExample) |